Onboard, tethered IL-12 boosts potency of the Tmod NOT gate and preserves selectivity
Background To reach their full potential in cancer therapy, immune cells engineered with synthetic constructs must achieve the challenging dual objectives of potency and selectivity to overcome the key obstacle: non-specific cytotoxicity. These problems are especially challenging for solid tumor the...
Sparad:
| Huvudupphov: | , , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
BMJ Publishing Group
2025-05-01
|
| Serie: | Journal for ImmunoTherapy of Cancer |
| Länkar: | https://jitc.bmj.com/content/13/5/e010976.full |
| Taggar: |
Inga taggar, Lägg till första taggen!
|